Production of new dietetic milk products for risk populations based on qualitative and quantitative analysis of health risk markers in milk consumption

Link to this page

info:eu-repo/grantAgreement/MESTD/Technological Development (TD or TR)/31060/RS//

Production of new dietetic milk products for risk populations based on qualitative and quantitative analysis of health risk markers in milk consumption (en)
Производња нових дијететских млечних производа за ризичне популације заснована на квалитативној и квантитативној анализи биохемијских маркера здравственог ризика конзумирања млека (sr)
Proizvodnja novih dijetetskih mlečnih proizvoda za rizične populacije zasnovana na kvalitativnoj i kvantitativnoj analizi biohemijskih markera zdravstvenog rizika konzumiranja mleka (sr_RS)
Authors

Publications

Benzimidazole-based dual dipeptidyl peptidase-4 and xanthine oxidase inhibitors

Tomović, Katarina; Ilić, Budimir S.; Smelcerović, Zaklina; Miljković, Marija; Yancheva, Denitsa; Kojić, Milan; Mavrova, Anelia Ts; Kocić, Gordana; Smelcerović, Andrija

(Elsevier Ireland Ltd, Clare, 2020)

TY  - JOUR
AU  - Tomović, Katarina
AU  - Ilić, Budimir S.
AU  - Smelcerović, Zaklina
AU  - Miljković, Marija
AU  - Yancheva, Denitsa
AU  - Kojić, Milan
AU  - Mavrova, Anelia Ts
AU  - Kocić, Gordana
AU  - Smelcerović, Andrija
PY  - 2020
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1376
UR  - http://intor.torlakinstitut.com/handle/123456789/699
AB  - Multiple-targeting compounds might reduce complex polypharmacy of multifactorial diseases, such as diabetes, and contribute to the greater therapeutic success. Targeting reactive oxygen species-producing enzymes, as xanthine oxidase (XO), might suppress progression of diabetes-associated vascular complications. In this study a small series of benzimidazole derivatives (1-9) was evaluated for inhibitory activity against dipeptidyl peptidase-4 (DPP-4) and XO. One 1,3-disubstituted-benzimidazole-2-imine (5) and 1,3-thiazolo [3,2-a] benzimidazolone derivative (8) were shown as effective dual DPP-4 and XO inhibitors, with IC50 values lower than 200 mu M, and predicted binding modes with both target enzymes. Both selected dual inhibitors (compounds 5 and 8) did not show cytotoxicity to a greater extent on Caco-2 cells even at concentration of 250 mu M. These structures represent new non-purine scaffolds bearing two therapeutic functionalities, being DPP-4 and XO inhibitors, more favorable in comparison to DPP-4 inhibitors with DPP-4 as a single target due to pleiotropic effects of XO inhibition.
PB  - Elsevier Ireland Ltd, Clare
T2  - Chemico-Biological Interactions
T1  - Benzimidazole-based dual dipeptidyl peptidase-4 and xanthine oxidase inhibitors
VL  - 315
DO  - 10.1016/j.cbi.2019.108873
ER  - 
@article{
author = "Tomović, Katarina and Ilić, Budimir S. and Smelcerović, Zaklina and Miljković, Marija and Yancheva, Denitsa and Kojić, Milan and Mavrova, Anelia Ts and Kocić, Gordana and Smelcerović, Andrija",
year = "2020",
abstract = "Multiple-targeting compounds might reduce complex polypharmacy of multifactorial diseases, such as diabetes, and contribute to the greater therapeutic success. Targeting reactive oxygen species-producing enzymes, as xanthine oxidase (XO), might suppress progression of diabetes-associated vascular complications. In this study a small series of benzimidazole derivatives (1-9) was evaluated for inhibitory activity against dipeptidyl peptidase-4 (DPP-4) and XO. One 1,3-disubstituted-benzimidazole-2-imine (5) and 1,3-thiazolo [3,2-a] benzimidazolone derivative (8) were shown as effective dual DPP-4 and XO inhibitors, with IC50 values lower than 200 mu M, and predicted binding modes with both target enzymes. Both selected dual inhibitors (compounds 5 and 8) did not show cytotoxicity to a greater extent on Caco-2 cells even at concentration of 250 mu M. These structures represent new non-purine scaffolds bearing two therapeutic functionalities, being DPP-4 and XO inhibitors, more favorable in comparison to DPP-4 inhibitors with DPP-4 as a single target due to pleiotropic effects of XO inhibition.",
publisher = "Elsevier Ireland Ltd, Clare",
journal = "Chemico-Biological Interactions",
title = "Benzimidazole-based dual dipeptidyl peptidase-4 and xanthine oxidase inhibitors",
volume = "315",
doi = "10.1016/j.cbi.2019.108873"
}
Tomović, K., Ilić, B. S., Smelcerović, Z., Miljković, M., Yancheva, D., Kojić, M., Mavrova, A. T., Kocić, G.,& Smelcerović, A.. (2020). Benzimidazole-based dual dipeptidyl peptidase-4 and xanthine oxidase inhibitors. in Chemico-Biological Interactions
Elsevier Ireland Ltd, Clare., 315.
https://doi.org/10.1016/j.cbi.2019.108873
Tomović K, Ilić BS, Smelcerović Z, Miljković M, Yancheva D, Kojić M, Mavrova AT, Kocić G, Smelcerović A. Benzimidazole-based dual dipeptidyl peptidase-4 and xanthine oxidase inhibitors. in Chemico-Biological Interactions. 2020;315.
doi:10.1016/j.cbi.2019.108873 .
Tomović, Katarina, Ilić, Budimir S., Smelcerović, Zaklina, Miljković, Marija, Yancheva, Denitsa, Kojić, Milan, Mavrova, Anelia Ts, Kocić, Gordana, Smelcerović, Andrija, "Benzimidazole-based dual dipeptidyl peptidase-4 and xanthine oxidase inhibitors" in Chemico-Biological Interactions, 315 (2020),
https://doi.org/10.1016/j.cbi.2019.108873 . .
11
14

Benzimidazole-based dual dipeptidyl peptidase-4 and xanthine oxidase inhibitors

Tomović, Katarina; Ilić, Budimir S.; Smelcerović, Zaklina; Miljković, Marija; Yancheva, Denitsa; Kojić, Milan; Mavrova, Anelia Ts; Kocić, Gordana; Smelcerović, Andrija

(Elsevier Ireland Ltd, Clare, 2020)

TY  - JOUR
AU  - Tomović, Katarina
AU  - Ilić, Budimir S.
AU  - Smelcerović, Zaklina
AU  - Miljković, Marija
AU  - Yancheva, Denitsa
AU  - Kojić, Milan
AU  - Mavrova, Anelia Ts
AU  - Kocić, Gordana
AU  - Smelcerović, Andrija
PY  - 2020
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1376
UR  - http://intor.torlakinstitut.com/handle/123456789/698
AB  - Multiple-targeting compounds might reduce complex polypharmacy of multifactorial diseases, such as diabetes, and contribute to the greater therapeutic success. Targeting reactive oxygen species-producing enzymes, as xanthine oxidase (XO), might suppress progression of diabetes-associated vascular complications. In this study a small series of benzimidazole derivatives (1-9) was evaluated for inhibitory activity against dipeptidyl peptidase-4 (DPP-4) and XO. One 1,3-disubstituted-benzimidazole-2-imine (5) and 1,3-thiazolo [3,2-a] benzimidazolone derivative (8) were shown as effective dual DPP-4 and XO inhibitors, with IC50 values lower than 200 mu M, and predicted binding modes with both target enzymes. Both selected dual inhibitors (compounds 5 and 8) did not show cytotoxicity to a greater extent on Caco-2 cells even at concentration of 250 mu M. These structures represent new non-purine scaffolds bearing two therapeutic functionalities, being DPP-4 and XO inhibitors, more favorable in comparison to DPP-4 inhibitors with DPP-4 as a single target due to pleiotropic effects of XO inhibition.
PB  - Elsevier Ireland Ltd, Clare
T2  - Chemico-Biological Interactions
T1  - Benzimidazole-based dual dipeptidyl peptidase-4 and xanthine oxidase inhibitors
VL  - 315
DO  - 10.1016/j.cbi.2019.108873
ER  - 
@article{
author = "Tomović, Katarina and Ilić, Budimir S. and Smelcerović, Zaklina and Miljković, Marija and Yancheva, Denitsa and Kojić, Milan and Mavrova, Anelia Ts and Kocić, Gordana and Smelcerović, Andrija",
year = "2020",
abstract = "Multiple-targeting compounds might reduce complex polypharmacy of multifactorial diseases, such as diabetes, and contribute to the greater therapeutic success. Targeting reactive oxygen species-producing enzymes, as xanthine oxidase (XO), might suppress progression of diabetes-associated vascular complications. In this study a small series of benzimidazole derivatives (1-9) was evaluated for inhibitory activity against dipeptidyl peptidase-4 (DPP-4) and XO. One 1,3-disubstituted-benzimidazole-2-imine (5) and 1,3-thiazolo [3,2-a] benzimidazolone derivative (8) were shown as effective dual DPP-4 and XO inhibitors, with IC50 values lower than 200 mu M, and predicted binding modes with both target enzymes. Both selected dual inhibitors (compounds 5 and 8) did not show cytotoxicity to a greater extent on Caco-2 cells even at concentration of 250 mu M. These structures represent new non-purine scaffolds bearing two therapeutic functionalities, being DPP-4 and XO inhibitors, more favorable in comparison to DPP-4 inhibitors with DPP-4 as a single target due to pleiotropic effects of XO inhibition.",
publisher = "Elsevier Ireland Ltd, Clare",
journal = "Chemico-Biological Interactions",
title = "Benzimidazole-based dual dipeptidyl peptidase-4 and xanthine oxidase inhibitors",
volume = "315",
doi = "10.1016/j.cbi.2019.108873"
}
Tomović, K., Ilić, B. S., Smelcerović, Z., Miljković, M., Yancheva, D., Kojić, M., Mavrova, A. T., Kocić, G.,& Smelcerović, A.. (2020). Benzimidazole-based dual dipeptidyl peptidase-4 and xanthine oxidase inhibitors. in Chemico-Biological Interactions
Elsevier Ireland Ltd, Clare., 315.
https://doi.org/10.1016/j.cbi.2019.108873
Tomović K, Ilić BS, Smelcerović Z, Miljković M, Yancheva D, Kojić M, Mavrova AT, Kocić G, Smelcerović A. Benzimidazole-based dual dipeptidyl peptidase-4 and xanthine oxidase inhibitors. in Chemico-Biological Interactions. 2020;315.
doi:10.1016/j.cbi.2019.108873 .
Tomović, Katarina, Ilić, Budimir S., Smelcerović, Zaklina, Miljković, Marija, Yancheva, Denitsa, Kojić, Milan, Mavrova, Anelia Ts, Kocić, Gordana, Smelcerović, Andrija, "Benzimidazole-based dual dipeptidyl peptidase-4 and xanthine oxidase inhibitors" in Chemico-Biological Interactions, 315 (2020),
https://doi.org/10.1016/j.cbi.2019.108873 . .
11
14

Benzo[4,5]thieno[2,3-d]pyrimidine phthalimide derivative, one of the rare noncompetitive inhibitors of dipeptidyl peptidase-4

Tomović, Katarina; Ilić, Budimir S.; Miljković, Marija; Dimov, Stefan; Yancheva, Denitsa; Kojić, Milan; Mavrova, Anelia T.; Kocić, Gordana; Smelcerović, Andrija

(Wiley-V C H Verlag Gmbh, Weinheim, 2019)

TY  - JOUR
AU  - Tomović, Katarina
AU  - Ilić, Budimir S.
AU  - Miljković, Marija
AU  - Dimov, Stefan
AU  - Yancheva, Denitsa
AU  - Kojić, Milan
AU  - Mavrova, Anelia T.
AU  - Kocić, Gordana
AU  - Smelcerović, Andrija
PY  - 2019
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1396
UR  - http://intor.torlakinstitut.com/handle/123456789/700
AB  - A small library of benzo[4,5]thieno[2,3-d]pyrimidine phthalimide and amine derivatives was evaluated for inhibitory activity against dipeptidyl peptidase-4 (DPP-4). The phthalimide derivatives exhibited better activity than the amine precursors, with 2-(2-(3-chlorobenzyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)isoindoline-1,3-dione (compound 14) as the most effective inhibitor (IC50 = 34.17 +/- 5.11 mu M). The five most potent selected inhibitors did not show cytotoxicity to a greater extent on Caco-2 cells, even at a concentration of 250 mu M. Compound 14 is considered as a novel representative of the rare noncompetitive DPP-4 inhibitors. Molecular docking and dynamics simulation indicated the importance of the Tyr547, Lys554, and Trp629 residues of DPP-4 in the formation of the enzyme-inhibitor complex. These observations could be potentially utilized for the rational design and optimization of novel (structurally similar, with phthalimide moiety, or different) noncompetitive DPP-4 inhibitors, which are anyway rare, but favorable in terms of the saturation of substrate competition.
PB  - Wiley-V C H Verlag Gmbh, Weinheim
T2  - Archiv Der Pharmazie
T1  - Benzo[4,5]thieno[2,3-d]pyrimidine phthalimide derivative, one of the rare noncompetitive inhibitors of dipeptidyl peptidase-4
IS  - 1
VL  - 353
DO  - 10.1002/ardp.201900238
ER  - 
@article{
author = "Tomović, Katarina and Ilić, Budimir S. and Miljković, Marija and Dimov, Stefan and Yancheva, Denitsa and Kojić, Milan and Mavrova, Anelia T. and Kocić, Gordana and Smelcerović, Andrija",
year = "2019",
abstract = "A small library of benzo[4,5]thieno[2,3-d]pyrimidine phthalimide and amine derivatives was evaluated for inhibitory activity against dipeptidyl peptidase-4 (DPP-4). The phthalimide derivatives exhibited better activity than the amine precursors, with 2-(2-(3-chlorobenzyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)isoindoline-1,3-dione (compound 14) as the most effective inhibitor (IC50 = 34.17 +/- 5.11 mu M). The five most potent selected inhibitors did not show cytotoxicity to a greater extent on Caco-2 cells, even at a concentration of 250 mu M. Compound 14 is considered as a novel representative of the rare noncompetitive DPP-4 inhibitors. Molecular docking and dynamics simulation indicated the importance of the Tyr547, Lys554, and Trp629 residues of DPP-4 in the formation of the enzyme-inhibitor complex. These observations could be potentially utilized for the rational design and optimization of novel (structurally similar, with phthalimide moiety, or different) noncompetitive DPP-4 inhibitors, which are anyway rare, but favorable in terms of the saturation of substrate competition.",
publisher = "Wiley-V C H Verlag Gmbh, Weinheim",
journal = "Archiv Der Pharmazie",
title = "Benzo[4,5]thieno[2,3-d]pyrimidine phthalimide derivative, one of the rare noncompetitive inhibitors of dipeptidyl peptidase-4",
number = "1",
volume = "353",
doi = "10.1002/ardp.201900238"
}
Tomović, K., Ilić, B. S., Miljković, M., Dimov, S., Yancheva, D., Kojić, M., Mavrova, A. T., Kocić, G.,& Smelcerović, A.. (2019). Benzo[4,5]thieno[2,3-d]pyrimidine phthalimide derivative, one of the rare noncompetitive inhibitors of dipeptidyl peptidase-4. in Archiv Der Pharmazie
Wiley-V C H Verlag Gmbh, Weinheim., 353(1).
https://doi.org/10.1002/ardp.201900238
Tomović K, Ilić BS, Miljković M, Dimov S, Yancheva D, Kojić M, Mavrova AT, Kocić G, Smelcerović A. Benzo[4,5]thieno[2,3-d]pyrimidine phthalimide derivative, one of the rare noncompetitive inhibitors of dipeptidyl peptidase-4. in Archiv Der Pharmazie. 2019;353(1).
doi:10.1002/ardp.201900238 .
Tomović, Katarina, Ilić, Budimir S., Miljković, Marija, Dimov, Stefan, Yancheva, Denitsa, Kojić, Milan, Mavrova, Anelia T., Kocić, Gordana, Smelcerović, Andrija, "Benzo[4,5]thieno[2,3-d]pyrimidine phthalimide derivative, one of the rare noncompetitive inhibitors of dipeptidyl peptidase-4" in Archiv Der Pharmazie, 353, no. 1 (2019),
https://doi.org/10.1002/ardp.201900238 . .
4
2
5